Memphis, TNNCT07052370Now EnrollingIRB Ready

Hematologic Malignancy Clinical Trial in Memphis, TN

Access cutting-edge hematologic malignancy treatment through this phase 1 clinical trial at a research site in Memphis. Study-provided care at no cost to qualified participants.

Sponsored by St. Jude Children's Research Hospital

Quick Self-Assessment

See if you qualify for this Memphis location

Preparing your pre-screening questions…

Expert Care in Memphis

Access hematologic malignancy specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related hematologic malignancy treatment provided free

Apply for This Memphis Location

Check if you qualify for this hematologic malignancy clinical trial in Memphis, TN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Memphis

    Convenient for TN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Memphis site if eligible
  4. 4Begin participation

About This Hematologic Malignancy Study in Memphis

This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: \- To assess the safety and feasibility of early CD45RA-depleted DLI administration. The secondary objectives are * To assess the safety and feasibility of the addition of blinatumomab in the early post-transplant period in patients with CD19+ malignancy. * To measure and describe the pharmacokinetics of rabbit ATG in HCT recipients on this study.

Sponsor: St. Jude Children's Research Hospital

Who Can Participate

Inclusion Criteria

Age less than or equal to 21 years
High risk hematologic malignancy whereas allogeneic transplantation is the current standard of care. This includes (but is not limited to):
High risk ALL in CR1 or CR2,
any ALL in CR3 or subsequent;
AML in high risk CR1 (AML diagnosis includes myeloid sarcoma),
any AML in CR2 or subsequent,
any therapy related AML;
MDS (primary or secondary),
NK cell, biphenotypic, or undifferentiated leukemia/lymphoma in CR1 or subsequent;
CML in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor, or a history of blast crisis.
If prior CNS leukemia, it must be treated and in CNS CR
Left ventricular ejection fraction \> 40%, or shortening fraction ≥ 25%
Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2
Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)
Bilirubin ≤ 3 times the upper limit of normal for age
Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age Donor:
At least single haplotype matched (≥ 4 of 8) family member
At least 18 years of age
HIV negative
Regarding donation eligibility, is identified as either:
Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR
Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271

Exclusion Criteria

Has a suitable HLA-identical sibling or suitable 12/12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame.
Any other active malignancy other than the one for which this HCT is indicated
Received a prior allogeneic HCT at any time
Received an autologous HCT within the previous 6 months
Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment
Breast feeding
Any current uncontrolled bacterial, fungal or viral infection Donor:
Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female
If female, breast feeding

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Memphis?

Yes, this clinical trial (NCT07052370) has an active research site in Memphis, TN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hematologic Malignancy Treatment Options in Memphis, TN

If you're searching for hematologic malignancy treatment options in Memphis, TN, this clinical trial (NCT07052370) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Memphis research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced hematologic malignancy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hematologic malignancy clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Memphis, TN

See all interstitial cystitis clinical trials recruiting in Memphis — not just this study.

Browse Interstitial Cystitis Trials in Memphis →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Memphis?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Memphis, TN